Powder: -20°C for 3 years | In solvent: -80°C for 1 year
(E/Z)-BCI (NSC-150117), a dual-specificity phosphatase 6 (DUSP6) inhibitor with anti-inflammatory properties, reduces LPS-induced inflammatory mediators and ROS production in macrophage cells by activating the Nrf2 signaling axis and inhibiting the NF-κB pathway.
Pack Size | Availability | Price/USD | Quantity |
---|---|---|---|
1 mg | In stock | $ 121.00 | |
5 mg | In stock | $ 248.00 | |
10 mg | In stock | $ 495.00 | |
25 mg | In stock | $ 791.00 | |
50 mg | In stock | $ 1,120.00 | |
100 mg | In stock | $ 1,490.00 | |
500 mg | In stock | $ 2,970.00 | |
1 mL * 10 mM (in DMSO) | In stock | $ 289.00 |
Description | (E/Z)-BCI (NSC-150117), a dual-specificity phosphatase 6 (DUSP6) inhibitor with anti-inflammatory properties, reduces LPS-induced inflammatory mediators and ROS production in macrophage cells by activating the Nrf2 signaling axis and inhibiting the NF-κB pathway. |
In vitro | (E/Z)-BCI hydrochloride (2-10 μM;?72 hours) significantly decreases cell viability in a time and dose-dependent manner in gastric epithelial cell GES1, GC cell lines, and AGS cell lines.?(E/Z)-BCI hydrochloride (0.5-4 μM;?24 hours) significantly inhibits DUSP6 expression in LPS-activated macrophages. (E/Z)-BCI hydrochloride inhibits cell proliferation, migration, and invasion in a receptor-independent manner and enhances Cisplatin (CDDP) cytotoxicity (enhances CDDP-induced cell death and apoptosis) at pharmacological concentrations in gastric cancer (GC) cells.?(E/Z)-BCI hydrochloride (0.5-2 μM;?24 hours) treatment significantly inhibits the expression of IL-1β, TNF-α, and IL-6 mRNA in LPS-activated macrophages.?(E/Z)-BCI hydrochloride decreases ROS production and activates the Nrf2 pathway in LPS-activated macrophages.? |
In vivo | (E/Z)-BCI hydrochloride treatment enhances cisplatin efficacy in PDX models. |
Synonyms | NSC 150117 |
Molecular Weight | 317.42 |
Formula | C22H23NO |
CAS No. | 15982-84-0 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Ethanol: 20mg/mL (60.00mM), sonification is recommended.
DMSO: 60mg/mL (189.02mM), sonification is recommended.
You can also refer to dose conversion for different animals. More
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
(E/Z)-BCI 15982-84-0 Apoptosis Metabolism Phosphatase NSC150117 ROS NSC 150117 death LPS gastric cancer anti-inflammatory NF-κB inhibit Inhibitor (E/Z) BCI Nrf2 (E/Z)BCI NSC-150117 ERK DUSP6 inhibitor